Strides Pharma Science enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


10,116	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
137	189	182	267	354
54.0	41.8	34.6	−53.9	−39.4
1,669	1,669	1,796	2,415	2,774
11,701	—	—	—	—
1,531	1,480	1,614	2,148	2,420
₹1,269.50	—	—	—	—

5,139	4,818	4,382	4,486	4,947
32.5%	34.6%	41.0%	53.8%	56.1%
0.14×	—	—	—	—

2.24×	—	—	—	—
12.24×	—	—	—	—
15.84×	—	—	—	—
41.85×	—	—	—	—
5,213	4,859	4,565	4,051	3,688
956	925	803	743	430
739	723	611	523	187
—	703	684	701	44.4
280	280	442	583	−50.5
—	256	402	426	−185
—	423	242	118	94.9

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

STAR₹1,097.50

Strides Pharma Science Ltd.

· Pharma & Health

₹ CrorePeersSPARC SUPRIYA SHILPAMED THYROCARE RUBICON VIYASH YATHARTH PARKHOSPSMcap ₹10,116 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	10,116.0
- Cash, Equiv & ST Investments	354.3	266.8	182.1	188.7	137.3
+ Minority Interest	-39.4	-53.9	34.6	41.8	54.0
+ Total Debt	2,774.5	2,414.5	1,795.6	1,668.7	1,668.7
Enterprise Value	—	—	—	—	11,701.4
Net Debt (memo)	2,420.1	2,147.7	1,613.5	1,480.0	1,531.4
EV per Share	—	—	—	—	1,269.50

Total Capital	4,947.3	4,486.2	4,382.1	4,818.0	5,139.2
Total Debt/Total Capital	56.08	53.82	40.98	34.63	32.47
Total Debt/EV	—	—	—	—	0.14

EV/Sales	—	—	—	—	2.24
EV/EBITDA	—	—	—	—	12.24
EV/EBIT	—	—	—	—	15.84
EV/Free Cash Flow	—	—	—	—	41.85
Reference Items — Trailing FY Values
Sales	3,688.4	4,051.1	4,565.3	4,858.7	5,213.3
EBITDA	430.2	743.3	802.8	925.3	956.3
EBIT	186.9	522.6	610.6	722.9	738.9
Operating Cash Flow	44.4	701.1	684.4	702.5	—
Free Cash Flow	-50.5	582.9	441.9	279.6	279.6
FCFF (free cash flow to the firm)	-185.1	425.9	402.1	255.9	—
Capital Expenditure	94.9	118.2	242.5	422.9	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.